CTLA-4-Directed Therapy in Squamous NSCLC

In this segment, the panel explains the biological rationale for combining CTLA-4 and PD-1 inhibition in advanced squamous non-small cell lung cancer (NSCLC). Dr. Narjust Florez describes CTLA-4 inhibition as acting earlier in T-cell activation, particularly during the priming phase in lymph nodes, whereas PD-1 inhibition primarily affects T-cell activity within the tumor microenvironment. The discussion highlights how dual checkpoint inhibition can enhance immune activation but may also increase systemic immune-related toxicities. Dr. Christian Rolfo reviews the clinical development of CTLA-4-directed therapies in NSCLC, including earlier studies that did not demonstrate benefit and more recent trials that have supported renewed interest in dual immunotherapy. The panel then considers newer CTLA-4-directed agents designed to provide greater selectivity and potentially reduce toxicity. The experts also discuss challenges specific to patients with squamous NSCLC, including comorbidities, symptomatic disease, limited pulmonary reserve, and the need for clinical trial designs that allow patients to receive treatment quickly.